



Chongqing Sintaho Pharmaceutical Co., Ltd.



# PRODUCT LIST 2024

Active  
Pharmaceutical  
Ingredients

## Established Products

OTHER THERAPY AREA	PRODUCT NAME	CAS#
Oncology	Eribulin Mesylate	441045-17-6
	Tirbanibulin	897016-82-9
	Azacitidine	320-67-2
	Paclitaxel Semi-Synthetic	33069-62-4
	Docetaxel Anhydrous	114977-28-5
	Cabazitaxel Acetone Solvate	1426815-65-7
	Carfilzomib	868540-17-4
	Ixazomib Citrate	1072833-77-2
	Pemetrexed Disodium Heptahydrate	357166-29-1

## Under Development Products

OTHER THERAPY AREA	PRODUCT NAME	CAS#
Oncology	Deruxtecan	1599440-13-7
	Olaparib	763113-22-0
	Lurbinectedin	497871-47-3
	Pirtobrutinib	2101700-15-4
Metabolic Disease (and others)	Orforglipron calcium hydrate	2212021-26-4
	Semaglutide	910463-68-2
	Semaglutide N-1 (SE02)	NA
	tBuO-Ste-Glu(AEEA-AEEA-OH)-OtBu	1118767-16-0
	Salcaprozate Sodium (SNAC)	203787-91-1
	Tirzepatide	2023788-19-2
CNS	Suzetrigine	2649467-58-1
	Cariprazine	839712-12-8

※: Various ADC compounds are available, covering linkers, payloads and linker-payload compounds.

**Disclaimer:** No information in this catalog - including any reference to any product or service - constitutes an offer for sale, or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, the research quantities of such products may be offered for the purpose of regulatory submissions, wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the patent scenario for their respective markets and will be responsible for all patent related liabilities.